Biologic
RCSB PDB 5Y9J
Belimumab
Benlysta
- Mechanism of action
- BLyS/BAFF antagonist (mAb)
- In plain language
- A lab-made antibody that soaks up BLyS, a survival signal B cells need, so fewer of the misguided immune cells that attack the body's own tissues survive.
- How it works
- Belimumab is a human IgG1 monoclonal antibody that binds soluble B-lymphocyte stimulator (BLyS, also known as BAFF), preventing it from engaging its receptors on B cells. By neutralizing this survival cytokine, belimumab reduces the survival of B cells, including autoreactive clones, and decreases their differentiation into immunoglobulin-secreting plasma cells. It does not directly bind B cells or deplete them via cytotoxicity, distinguishing its mechanism from B-cell-depleting agents like rituximab.
- Therapeutic applications
- Indicated in patients aged 5 years and older for active systemic lupus erythematosus as add-on therapy to standard treatment, and for active lupus nephritis, also as add-on therapy.
- Class
- Monoclonal antibody
- Therapeutic area
- Immunology
View
Related compounds